{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IM+placebo",
    "query": {
      "intervention": "IM placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 406,
    "total_pages": 41,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IM+placebo&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T19:10:31.012Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02915016",
      "title": "Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DNA-HIV-PT123 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent Subtype C gp120/MF59 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent Subtype C gp120/AS01B vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 334,
      "start_date": "2016-12-07",
      "completion_date": "2020-02-12",
      "has_results": true,
      "last_update_posted_date": "2022-04-29",
      "last_synced_at": "2026-09-04T19:10:31.012Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02915016"
    },
    {
      "nct_id": "NCT05375838",
      "title": "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "mRNA-1073",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1010",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 550,
      "start_date": "2022-05-13",
      "completion_date": "2022-12-29",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-09-04T19:10:31.012Z",
      "location_count": 14,
      "location_summary": "Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Norfolk",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05375838"
    },
    {
      "nct_id": "NCT03870880",
      "title": "Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Risperidone ISM 75 mg",
          "type": "DRUG"
        },
        {
          "name": "Risperidone ISM 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rovi Pharmaceuticals Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 215,
      "start_date": "2017-08-25",
      "completion_date": "2020-01-08",
      "has_results": true,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-09-04T19:10:31.012Z",
      "location_count": 13,
      "location_summary": "Rogers, Arkansas • Garden Grove, California • Long Beach, California + 10 more",
      "locations": [
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pico Rivera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03870880"
    },
    {
      "nct_id": "NCT07454915",
      "title": "PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Intraepithelial Neoplasia Grade 2/3",
        "Human Papilloma Virus Infection Type 16"
      ],
      "interventions": [
        {
          "name": "PVX4 Combination Product",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "PapiVax Biotech, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 138,
      "start_date": "2026-04-01",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-09-04T19:10:31.012Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07454915"
    },
    {
      "nct_id": "NCT02294058",
      "title": "Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Placebo to ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo to interferon beta-1a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1346,
      "start_date": "2014-12-03",
      "completion_date": "2016-12-22",
      "has_results": true,
      "last_update_posted_date": "2020-11-25",
      "last_synced_at": "2026-09-04T19:10:31.012Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02294058"
    },
    {
      "nct_id": "NCT05422326",
      "title": "A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human",
        "Influenza in Birds",
        "Respiratory Tract Infections",
        "Infections",
        "Orthomyxoviridae Infections",
        "RNA Virus Infections",
        "Virus Diseases",
        "Respiratory Tract Diseases"
      ],
      "interventions": [
        {
          "name": "aH5N6c on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aH5N6c on Day 22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo on Day 22",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2022-07-18",
      "completion_date": "2023-03-24",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-09-04T19:10:31.012Z",
      "location_count": 18,
      "location_summary": "Huntsville, Alabama • Tempe, Arizona • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05422326"
    },
    {
      "nct_id": "NCT02337855",
      "title": "A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schistosomiasis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Sm-TSP-2/Alhydrogel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sm-TSP-2/Alhydrogel/GLA-AF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 72,
      "start_date": "2015-02-04",
      "completion_date": "2017-01-27",
      "has_results": false,
      "last_update_posted_date": "2017-06-26",
      "last_synced_at": "2026-09-04T19:10:31.012Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02337855"
    },
    {
      "nct_id": "NCT01709019",
      "title": "RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus (RSV)"
      ],
      "interventions": [
        {
          "name": "Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2012-10",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-03-05",
      "last_synced_at": "2026-09-04T19:10:31.012Z",
      "location_count": 4,
      "location_summary": "Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01709019"
    },
    {
      "nct_id": "NCT01333462",
      "title": "Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Volunteers"
      ],
      "interventions": [
        {
          "name": "NB-1008",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "NanoBio Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 199,
      "start_date": "2009-03",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2011-04-12",
      "last_synced_at": "2026-09-04T19:10:31.012Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01333462"
    },
    {
      "nct_id": "NCT01172054",
      "title": "Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "VAX128",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "VaxInnate Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 292,
      "start_date": "2010-07",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2012-07-31",
      "last_synced_at": "2026-09-04T19:10:31.012Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Lenexa, Kansas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01172054"
    }
  ]
}